

**Listing of Claims:**

The following listing of claims replaces all prior versions and listings of claims in the application. Please note that "Original" claims refer to claims as presented in International Application PCT/DK20043/000193.

1. (Amended) A variant of FVII or FVIIa, wherein said variant comprises 1-15 amino acid modifications as compared to hFVII or hFVIIa (SEQ ID NO:2), including at least one amino acid modification in a position selected from the group consisting of positions196, 237 and 341 as compared to hFVII or hFVIIa (SEQ ID NO:2).
2. (Cancelled)
3. (Amended) The variant of claim 1 ~~or 2~~, wherein said variant comprises a modification in position 196 as compared to hFVII or hFVIIa (SEQ ID NO:2).
4. (Original) The variant of claim 3, wherein said modification is a substitution.
5. (Original) The variant of claim 4, wherein said substitution is D196K or D196N.
6. (Amended) The variant of claim 1 ~~or 2~~, wherein said variant comprises a modification in position 237 as compared to hFVII or hFVIIa (SEQ ID NO:2).
7. (Original) The variant of claim 6, wherein said modification is a substitution.
8. (Original) The variant of claim 7, wherein said substitution is G237L.
9. (Original) The variant of claim 6, wherein said modification is an insertion.

-----  
10. (Original) The variant of claim 9, wherein said insertion is selected from the group consisting of G237GXX, G237GXXX and G237GXXXX, wherein X is any amino acid residue.

11. (Original) The variant of claim 10, wherein X is selected from the group consisting Ala, Val, Leu, Ile, Gly, Ser and Thr.

12. (Original) The variant of claim 11, wherein X is Ala.

13. (Amended) The variant of claim 12, wherein said ~~insertions are~~ insertion is G237GAA.

14. (Amended) The variant of claim 1 ~~or 2~~, wherein said variant comprises a modification in position 341 as compared to hFVII or hFVIIa (SEQ ID NO:2).

15. (Original) The variant of claim 14, wherein said modification is a substitution.

16. (Original) The variant of claim 15, wherein said substitution is K341Q.

17. (Amended) The variant of ~~any of claims 1-16~~ claim 1, wherein said variant comprises 1-10 further amino acid modifications.

18. – 53. (Cancelled)

54. (Amended) The variant of ~~any of the preceding claims~~ claim 1, wherein said variant is in its activated form.

55. (Amended) A nucleotide sequence encoding a variant as defined in ~~any of claims 1-54~~ claim 1.

56. (Original) An expression vector comprising a nucleotide sequence as defined in claim 55.

57. (Amended) A host cell comprising ~~a nucleotide sequence as defined in claim 55~~ or an expression vector as defined in claim 56.

58. (Original) The host cell of claim 57, wherein said host cell is a gamma-carboxylating cell capable of *in vivo* glycosylation.

59. (Amended) A composition comprising a variant as defined in ~~any of claims 1-54~~ claim 1 and at least one pharmaceutically acceptable carrier or excipient.

60. – 64. (Cancelled)

65. (Amended) A method for treating a mammal having a disease or a disorder wherein clot formation is desirable, comprising administering to a mammal in need thereof an effective amount of the variant ~~as defined in any of claims 1-54 or the composition of claim 59~~ of claim 1.

66. (Original) The method of claim 65, wherein said disease or disorder is selected from the group consisting of hemorrhages, including brain hemorrhages, severe uncontrolled bleedings, such as trauma, bleedings in patients undergoing transplantations or resection, variceal bleedings, and hemophilia.

67. (Original) The method of claim 66, wherein said disease or disorder is trauma.

68. (Original) The method of claim 66, wherein said disease or disorder is hemophilia.